What is claimed is:

1. A compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof,



（ I）

L_1 is a single bond or -C_{1-6} alkyl-;

R_1 is H, Cl, F, Br, I or C_{1-3} alkyl which is optionally substituted by 1, 2 or 3 R;

R_2 is selected from the group consisting of C_{1-3} heteroalkyl, 4-8 membered heterocycloalkyl, 5-10 membered heteroaryl, 4-8 membered partially unsaturated heterocycloalkyl, phenyl, C_{1-3} alkyl, C_{3-8} cycloalkyl, 4-8 membered heterocycloalkyl-O- and 5-10 membered heteroaryl-O-, each of which is optionally substituted by 1, 2 or 3 R;

R_3 is H or C_{1-3} alkyl;

each of R is independently H, Cl, F, Br, I, NH_2, OH or CN, or selected from the group consisting of C_{1-6} alkyl, C_{1-6} heteroalkyl, phenyl, phenyl-O-C(=O)- and 5-6 membered heteroaryl, each of which is optionally substituted by 1, 2 or 3 R';

each of R' is independently selected from the group consisting of Cl, F, Br, I, NH_2, CH_3, CN and $N(CH_3)_2$;

each of the “hetero” in the C_{1-3} heteroalkyl, 4-8 membered heterocycloalkyl, 5-10 membered heteroaryl, C_{1-6} heteroalkyl, 5-6 membered heteroaryl and 4-8 membered partially unsaturated heterocycloalkyl is independently selected from the group consisting of -S-, -O-, -NH-, N, -C(=O)-, -O-C(=O)-, -$S(=O)_2$-, -S(=O)-, -NH-C(=O)- and -NH-C(=O)-O-;

in any of the above cases, the number of the heteroatom or the heteroatomic group is independently 1, 2, 3 or 4.

2. The compound, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to claim 1, wherein, R is H, Cl, F, Br, I, NH_2, OH or CN, or selected from the group consisting of  , C_{1-3} alkyl, C_{1-6} alkyl-O-C(=O)-, C_{1-6} alkyl-C(=O)-, C_{1-3} alkyl-$S(=O)_2$-, C_{1-3} alkyl-S(=O)-, C_{1-3} alkylamino, phenyl, phenyl-O-C(=O)- and pyridyl, each of which is optionally substituted by 1, 2 or 3 R'.

3. The compound, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to claim 2, wherein, R is H, Cl, F, Br, I, NH_2, OH or CN, or selected

from the group consisting of CH_3,  , and , each of which is optionally substituted by 1, 2 or 3 R'.

4. The compound, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to claim 3, wherein, R is selected from the group consisting of H, Cl, F, Br, I, NH_2, OH, CH_3, CN,  ,  , and  .

5. The compound, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to any one of claims 1-4, wherein, R_1 is selected from the group consisting of H, Cl, F, Br, I, Me, Et,  and  .

6. The compound, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to any one of claims 1-4, wherein, R_2 is selected from the group consisting of C_{1-3} alkoxy, tetrahydrofuranyl, thiazolyl, 3-azabicyclo[3.1.0]hexyl, pyridyl, benzimidazolyl, thienyl, pyrazolyl, benzothiazolyl, imidazo[1,2-*a*]pyridyl, methyl, C_{1-3} alkylthio, C_{1-3} alkyl-$S(=O)_2$-, cyclopentyl, phenyl, azetidinyl, piperidinyl, pyrrolidinyl, oxazolyl, 2-oxo-pyrrolidinyl, 2(1*H*)-oxo-pyridinyl, cyclohexyl, cyclopropyl, 1,1-dioxo-isothiazolidinyl, pyrimidinyl, 1,3,4-thiadiazolyl, 2-oxo-oxazolidinyl, tetrahydropyranyl, cyclopentyl-O-, pyridyl-O-, oxepanyl, 1,4-dioxanyl, 1,4-dioxepanyl, morpholinyl and 2,3-dihydrobenzo[*b*][1,4]dioxinyl, each of which is optionally substituted by 1, 2 or 3 R.

7. The compound, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to claim 6, wherein, R_2 is selected from the group consisting of CH_3, 


, each of which is optionally substituted by 1, 2 or 3 R.

8. The compound, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to claim 7, wherein, R_2 is selected from the group consisting of




and .

9. The compound, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to any one of claims 1-4, wherein, L_1 is a single bond, CH_2,  or  .

10. The compound, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to any one of claims 1-4, wherein, R_3 is H, CH_3 or $-CH_2CH_3$.

11. The compound, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to any one of claims 1-4, wherein, the moiety  is selected from the group consisting of 



12. The compound, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to any one of claims 1-5 or 9-10, which is selected from the group consisting of:



(I -1) ,



(I -2) ,



(I -3) ,



(I -4) ,



(I -5) and



(I -6) ,

wherein,

m is 1, 2 or 3;

n is 1 or 2;

r is 0 or 1;

T_1 is N or CH;

R is as defined in any one of claims 1-4;

L_1 is as defined in claim 1 or 9;

R_1 is as defined in claim 1 or 5;

R_3 is as defined in claim 1 or 10.

13. The compound, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to claim 12, which is selected from the group consisting of:



(I -7) ,



(I -8) ,



(I -9)

,



(I -10)



(I -11)

and ,

wherein,

R is as defined in any one of claim 1-4;

L_1 is as defined in claim 1 or 9;

R_1 is as defined in claim 1 or 5;

R_3 is as defined in claim 1 or 10;

n is as defined in claim 12.

14. A compound, a stereoisomer thereof or a pharmaceutically acceptable salt thereof, which is selected from the group consisting of:



,



,



,



,



,



,



,



,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


























,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,


,

,

,

,

or

.

15. The compound, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to claim 14, which is selected from the group consisting of:


,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

and

.

16. A pharmaceutical composition comprising a therapeutically effective amount of the compound, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to any one of claims 1-15 as the active ingredient, and a pharmaceutically acceptable carrier.

17. A use of the compound, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to any one of claims 1-15 in manufacturing a medicament for treating hepatitis B.

18. A use of the pharmaceutical composition according claim 16 in manufacturing a medicament for treating hepatitis B.